case_images: PMC5950191_01
case_images: Barcharts of patient symptoms and corresponding RECIST 1.1 status (a) and T2W MRI signal changes (b)
case_images: 13569_2018_100_Fig1_HTML.jpg
case_images: PMC5950191_01_13569_2018_100_Fig1_HTML.jpg
case_images: Fig1
case_images: The majority of patients with symptomatic benefit did not have significant changes in size or signal on MRI (Fig. 1a, b). 
case_images: Kaplan-Meier progression free survival analysis after treatment with tamoxifen. Median PFS was 10 months (95% CI 6.4-24.6)
case_images: 13569_2018_100_Fig2_HTML.jpg
case_images: PMC5950191_01_13569_2018_100_Fig2_HTML.jpg
case_images: Fig2
case_images: Median progression-free survival (PFS) per RECIST 1.1 was 10 months with (95% CI 6.4-24.6); PFS at 1 and 2 years was 50% (95% CI 32-66) and 34% (95% CI 19-51), respectively (Fig. 2), with a median follow-up of 45.5 months (range 14-105). 
case_images: PMC5950191_02
case_images: Axial T2 weighted MRI images showing right anterior abdominal wall fibromatosis in a 35-year old male (a) and the corresponding MRI after 7 months of treatment with tamoxifen (b) show decrease in size and T2 signal
case_images: 13569_2018_100_Fig3_HTML.jpg
case_images: PMC5950191_02_13569_2018_100_Fig3_HTML.jpg
case_images: Fig3
case_images: The symptomatic improvement corresponded with a decrease in size and T2 signal on MRI (Fig. 3). 